Patents
Literature
43results about How to "More potent" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phenyl guanidine sodium channel blockers
InactiveUS6858615B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderStructural variableGuanidine
The present invention relates to a compound represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are as defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Phenolic guanidine sodium channel blockers
InactiveUS6858614B2Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderGuanidineSodium channel blocker
The present invention relates to compounds represented by formula (I): in which at least one of R3 and R4 is a group represented by formula (A): where the structural variables are defined herein. The compounds are useful for blocking sodium channels.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
InactiveUS7807834B2Prolonged pharmacodynamic half-lifeMore potent and/or absorbed less rapidlySenses disorderNervous disorderChannel blockerCalcium channel blocker
The present invention relates to group of pyrazinoylguanidine compounds useful as sodium channel blockers. The compounds may be used to promote promoting hydration of mucosal surfaces.
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
ActiveUS20080090841A1More specificLess reversibleAntibacterial agentsOrganic active ingredientsOtic AgentsOsmolyte
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20060142306A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderTreatment useChemistry
Owner:CYFI
Alaphatic pyrazinoylguanidine sodium channel blockers
ActiveUS20050080092A1Absorbed less rapidlyMore potentOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Poly aromatic pyrazinoylguanidine sodium channel blockers
ActiveUS8124607B2More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
InactiveUS8058278B2More specificAbsorbed less rapidlyAntibacterial agentsOrganic active ingredientsDiseaseOsmolyte
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
New capped pyrazinoylguanidine sodium channel blockers
InactiveUS20070032509A1Less surfaceLess reversibleSenses disorderNervous disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
ActiveUS20050228182A1More potent and/or absorbed less rapidlyLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20050113390A1More potentLess reversibleOrganic active ingredientsSenses disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Sodium channel blockers
InactiveUS20050113389A1More potentLess reversibleOrganic active ingredientsSenses disorderChemistryTreatment use
Owner:PARION SCI DURHAM NC
Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes
The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.
Owner:PARION SCI DURHAM NC
Capped pyrazinoylguanidine sodium channel blockers
ActiveUS20050080091A1Increased mucociliary clearanceAbsorbed less rapidlyBiocideSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
InactiveUS20130324559A1More potentLess reversibleOrganic active ingredientsSenses disorderAmino amideSodium channel blocker
Owner:PARION SCI DURHAM NC
Amidino derivatives and their use as thrombin inhibitors
InactiveUS6221898B1More efficaciousToxic reductionBiocidePeptide/protein ingredientsAmidino derivativeThrombin activity
There is provided compounds of formula I,wherein R1, R2, R3, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
Owner:ASTRAZENECA AB
Thiochromane derivatives and their use as thrombin inhibitors
InactiveUS6716834B2Toxic reductionLonger actingOrganic active ingredientsBiocideThrombusPharmaceutical drug
There is provided compounds of formulae I and IAwherein Y, R<1>, R<2>, R<3>, D<1 >and D<2 >have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
Owner:ASTRAZENECA AB
Amidinobenzylamine derivatives and their use as thrombin inhibitors
InactiveUS6599894B1Longer actingWide range of activitiesBiocidePeptide/protein ingredientsAnticoagulantThrombin activity
There is provided compounds of formula Iwherein R1, R2, Y, R3 and R4 have meanings given in the description which are useful as, or as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.
Owner:ASTRAZENECA AB
Amino acid derivatives and their use as thrombin inhibitors
InactiveUS6255301B1More efficaciousToxic reductionSilicon organic compoundsBiocideAnticoagulantThrombin activity
There is provided compounds of formula I,wherein R1, R2, R3, Rx, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required as in thrombosis or as anticoagulants.
Owner:ASTRAZENECA AB
Positive modulators of nicotinic acetylcholine receptors
InactiveUS20070179172A1More efficaciousLonger actingBiocideNervous disorderCompound (substance)Stereochemistry
Owner:ASTRAZENECA AB
Poly aromatic sodium channel blockers
ActiveUS20090214444A1More potentLess reversibleOrganic active ingredientsSenses disorderChannel blockerTreatment use
Owner:PARION SCI DURHAM NC
Positive modulators of nicotinic receptor agonists
InactiveUS20050245595A1Enhance efficacy of agonistRestore normal interneuronal communicationBiocideNervous disorderEnantiomerNicotinic Receptor Agonist
Owner:ASTRAZENECA AB
Optimized multi-epitope constructs and uses thereof
InactiveUS7507803B2Improve effectivenessImprove responseOrganic active ingredientsBiocidePeptide vaccineVaccine Immunogenicity
The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.
Owner:GENIMMUNE NV +1
Solvent resistant polymers
Owner:CENT MICHIGAN UNIV UNIV BOARD OF TRUSTEES
Solvent resistant polymers
What is disclosed relates to polymers that resist dissolution in organic solvents, are vasodilators, and are tunable explosives. These polymers also form solvent resistant coatings and solvent resistant fibers as well as bonding materials.
Owner:CENT MICHIGAN UNIV UNIV BOARD OF TRUSTEES
Solvent resistant polymers
What is disclosed relates to polymers that resist dissolution in organic solvents, are vasodilators, and are tunable explosives. These polymers also form solvent resistant coatings and solvent resistant fibers as well as bonding materials. Such polymers have the general formulae: and polymers corresponding to the formulae:
Owner:CENT MICHIGAN UNIV UNIV BOARD OF TRUSTEES
Metallodrugs having improved pharmacological properties and methods of manufacture and use thereof
InactiveUS8933016B2More potentBlocking the activity of these macromoleculesAntibacterial agentsBiocideClinical settingsMicrobial agent
It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and / or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.
Owner:METALLOPHARM
N-Oxo-Heterocycle and N-Oxo-Alkyl Quinoline-4-Carboxamides as Nk-3 Receptor Ligands
InactiveUS20080234269A1Easy to adjustLess side effectsBiocideNervous disorderQuinolineCombinatorial chemistry
Owner:ASTRAZENECA AB
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
